These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 14581334)

  • 1. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
    Trikha M; Corringham R; Klein B; Rossi JF
    Clin Cancer Res; 2003 Oct; 9(13):4653-65. PubMed ID: 14581334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of multiple myeloma.
    Huang YW; Vitetta ES
    Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
    Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
    Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
    Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin and multiple myeloma related anemia.
    Cucuianu A; Patiu M; Rusu A
    Med Hypotheses; 2006; 66(2):352-4. PubMed ID: 16226391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
    Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
    Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
    Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
    Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
    Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
    Ramsey S; Aitchison M; Graham J; McMillan DC
    BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
    Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
    Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 signaling pathway in targeted therapy for cancer.
    Guo Y; Xu F; Lu T; Duan Z; Zhang Z
    Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.